Horizon Therapeutics Public Limited Company

NasdaqGS:HZNP Stock Report

Market Cap: US$26.6b

Horizon Therapeutics Past Earnings Performance

Past criteria checks 1/6

Horizon Therapeutics has been growing earnings at an average annual rate of 32.8%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 28.5% per year. Horizon Therapeutics's return on equity is 8.2%, and it has net margins of 12%.

Key information

32.8%

Earnings growth rate

30.0%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate28.5%
Return on equity8.2%
Net Margin12.0%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Nov 25
These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Nov 02
Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Horizon pays HemoShear milestone payment under pact to develop gout therapies

Sep 21

Horizon Therapeutics announces $500M buyback program

Sep 09

Horizon Therapeutics to expand footprint in Ireland

Aug 29

Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Aug 22
Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Horizon Therapeutics: This Core Biotech Company Is On Sale

Aug 19

Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Aug 04
Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Aug 02
Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth

Jul 31

Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout

Jul 08

Revenue & Expenses Breakdown
Beta

How Horizon Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:HZNP Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 233,6444381,659516
31 Mar 233,5763721,623469
31 Dec 223,6295211,543438
30 Sep 223,7015741,592422
30 Jun 223,8137651,526354
31 Mar 223,7698621,511391
31 Dec 213,2265341,442345
30 Sep 212,9575521,297315
30 Jun 212,5575181,190254
31 Mar 212,1872801,029195
31 Dec 202,200390973129
30 Sep 201,819792880122
30 Jun 201,518517827161
31 Mar 201,376592772109
31 Dec 191,300573696103
30 Sep 191,2928268694
30 Jun 191,2829767491
31 Mar 191,2647767987
31 Dec 181,208-3868783
30 Sep 181,126-178680-65
30 Jun 181,073-275674-68
31 Mar 181,059-46066170
31 Dec 171,056-35065566
30 Sep 171,092-495680218
30 Jun 171,029-437653213
31 Mar 17997-21262661
31 Dec 16981-16660461
30 Sep 16915-1251749
30 Jun 16933-349647
31 Mar 168491446045
31 Dec 157574043842
30 Sep 15616-1633033
30 Jun 15465-1730226
31 Mar 15358-7724121
31 Dec 14297-26420917
30 Sep 14223-33518214
30 Jun 14172-34212511
31 Mar 14117-33311111
31 Dec 1374-1499210
30 Sep 1350-708512
30 Jun 1332-828114
31 Mar 1325-867415
31 Dec 1219-886917

Quality Earnings: HZNP has a large one-off loss of $131.0M impacting its last 12 months of financial results to 30th June, 2023.

Growing Profit Margin: HZNP's current net profit margins (12%) are lower than last year (20.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HZNP has become profitable over the past 5 years, growing earnings by 32.8% per year.

Accelerating Growth: HZNP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: HZNP had negative earnings growth (-42.7%) over the past year, making it difficult to compare to the Biotechs industry average (-42.7%).


Return on Equity

High ROE: HZNP's Return on Equity (8.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.